知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

4358 records (took 0.032 seconds)

    Skin care formulations and skin cancer treatment
    1.
    发明授权
    Skin care formulations and skin cancer treatment 有权

    公开(公告)号：US12233073B2

    公开(公告)日：2025-02-25

    申请号：US16620382

    申请日：2018-06-08

    Applicant: Regents of the University of Minnesota

    Inventor： Ann M. Bode ,  Zigang Dong ,  Eunmiri Roh

    IPC: A61K35/04 ,  A61K9/00 ,  A61K31/573 ,  A61K31/58 ,  A61P35/04 ,  A61K45/06

    Abstract: An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide.

    COMBINATION
    4.
    发明申请
    COMBINATION 有权

    公开(公告)号：US20250017947A1

    公开(公告)日：2025-01-16

    申请号：US18739657

    申请日：2024-06-11

    Applicant: Novartis AG

    Inventor： Mark J. Cornfeld ,  Rakesh Kumar ,  Shannon Renae Morris

    IPC: A61K31/58 ,  A61K31/4155 ,  A61K31/4375 ,  A61K45/06

    Abstract: A novel combination comprising a 17 α-hydroxylase/C17,20 lyase inhibitor, for example: (3β)-17-(pyridin-3-yl)androsta-5,18-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.

    DRY POWDER FOAMABLE FORMULATIONS FOR DELIVERY OF MEDICAMENTS THROUGH THE MUCOSA
    10.
    发明申请
    DRY POWDER FOAMABLE FORMULATIONS FOR DELIVERY OF MEDICAMENTS THROUGH THE MUCOSA 有权

    公开(公告)号：US20240398709A1

    公开(公告)日：2024-12-05

    申请号：US18695347

    申请日：2022-09-24

    Applicant: Chadwick Donaldson ,  Adam Haeberle ,  Joseph Fuisz

    Inventor： Chadwick Donaldson ,  Adam Haeberle ,  Joseph Fuisz

    IPC: A61K9/14 ,  A61K9/00 ,  A61K9/12 ,  A61K31/58 ,  A61K31/661 ,  A61P1/02

    Abstract: Embodiments include formulations and methods for oromucosal administration of a dry powder to create a topical foam composition to deliver medicaments to an interior mucosal space, such as the oral cavity, nasal cavity, rectal cavity, vaginal cavity or esophagus. The active agent can be amifostine, an antibiotic, an anti-fungal, a non-steroidal anti-inflammatory drug or a steroidal anti-inflammatory drug. Oromucosal delivery allows one to target oral epithelial cells. Embodiments also include methods of treating mucositis. Conventional formulations and methods are generally ineffective because drugs cannot be directed toward epithelial cells of the GI that are most susceptible to mucositis. The formulations described herein increase concentration, permeability and residence time at a target site. The formulations also allow stable forms of amifostine, which obviates difficulties associated with storing, dosing and administering the drug.

Patent Agency Ranking